Filing Details

Accession Number:
0001246360-14-001795
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-14 17:07:09
Reporting Period:
2014-03-12
Filing Date:
2014-03-14
Accepted Time:
2014-03-14 16:07:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
911326 Synageva Biopharma Corp GEVA Biological Products, (No Disgnostic Substances) (2836) 561808663
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532217 Chris Heberlig 33 Hayden Ave
Lexington MA 02421
Group Vice President, Finance No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-12 1,850 $1.70 2,042 No 4 M Direct
Common Stock Acquisiton 2014-03-12 820 $0.95 2,862 No 4 M Direct
Common Stock Acquisiton 2014-03-12 5,000 $23.00 7,862 No 4 M Direct
Common Stock Disposition 2014-03-12 700 $96.75 7,162 No 4 S Direct
Common Stock Disposition 2014-03-12 3,933 $98.49 3,229 No 4 S Direct
Common Stock Disposition 2014-03-12 3,037 $99.08 192 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-03-12 1,850 $0.00 1,850 $1.70
Common Stock Stock Option (Right to Buy) Disposition 2014-03-12 820 $0.00 820 $0.95
Common Stock Stock Option (Right to Buy) Disposition 2014-03-12 5,000 $0.00 5,000 $23.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,938 2021-05-25 No 4 M Direct
0 2019-12-15 No 4 M Direct
10,000 2021-12-20 No 4 M Direct
Footnotes
  1. The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 1, 2013.
  2. The stock option granted the reporting person an option to purchase 6,188 Shares. 25% of such Shares vested and became exercisable on 05/25/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
  3. The stock option granted the reporting person an option to purchase 2,820 Shares. 25% of such Shares vested and became exercisable on 09/25/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
  4. The stock option granted the reporting person an option to purchase 15,000 Shares. 25% of such Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
  5. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.36 to $97.10. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  6. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $97.77 to $98.75. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  7. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $98.79 to $99.29. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.